Document Detail


Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
MedLine Citation:
PMID:  10450539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Etofibrate is a hypolipemic drug belonging to the fibrate class. By improving the lipid profile, these drugs often exert a favorable influence on hemostatic risk factors of ischemic heart disease. We present a pilot study on the influence of etofibrate on lipids and lipoproteins in serum, as well as on factor VII and fibrinogen. The study group was comprised of 18 males, aged 52.5 +/- 7.3 years, with hypertriglyceridemia or mixed hyperlipoproteinemia and other risk factors of atherosclerosis, particularly insulin-dependent diabetes and arterial hypertension. The group was further divided into two subgroups depending on the coexistence of arterial hypertension. All patients received etofibrate 500 mg daily for 3 months. In comparison with initial values, a decrease in the following was noted for the whole study group: triglyceride level (226.0 +/- 27.1 vs. 288.0 +/- 51.9 mg/dl; p < 0.05), percent LDL-cholesterol (72.4 +/- 1.8 vs. 75.8 +/- 1.7; p < 0.05), apolipoprotein B (111.2 +/- 4.6 vs. 115.3 +/- 5.4 mg/dl; p < 0.05), atherogenic indices: LDL/HDL (5.06 +/- 0.58 vs. 5.95 +/- 0.50; p < 0.02) and apolipoprotein B and A (apoB/apoA) (0.92 +/- 0.04 vs. 1.02 +/- 0.06; p < 0.05). There was an increase in percent HDL-cholesterol (14.7 +/- 1.1 vs. 12.8 +/- 0.7; p < 0.05) and apoA (121.0 +/- 4.8 vs. 111.2 +/- 2.4 mg/dl; p < 0.05). A marked decrease in the level of factor VII (FVIIc) (114 +/- 5.9 vs. 136 +/- 5.3%; p < 0.001) and fibrinogen (2.95 +/- 0.17 vs. 3.58 +/- 0.17 g/l; p < 0.01) was found. Fibrinogen levels fell notably (3.09 +/- 0.30 vs. 3.87 +/- 0.34 g/l; p < 0.05) in the subgroup with arterial hypertension, and F1 + 2 markers tended to decline (2.32 +/- 0.53 vs. 2.74 +/- 0.37 nmol/l; NS). Patients with normals arterial pressure maintained their fibrinogen levels (3.23 +/- 0.24 vs. 3.36 +/- 0.26 g/l; NS). A positive correlation between FVIIc and F1 + 2 was observed during treatment. All results were expressed as arithmetic means +/- SE. The present study has demonstrated that etofibrate has hypolipemic, antithrombotic and antiatherosclerotic properties in patients with polymetabolic syndrome.
Authors:
M Jastrzebska; B Torbus-Lisiecka; J Pieczul-Mróz; K Chelstowski; J Kopciewicz; M Naruszewicz
Related Documents :
22052609 - Brain perfusion spect in patients with phaces syndrome under propranolol treatment.
21731249 - Comparison of oral hygiene and periodontal status in patients with clefts of palate and...
22535509 - Reduction in retinal nerve fiber layer thickness in migraine patients.
17485889 - Increased remnant lipoprotein in patients with coronary artery disease--evaluation util...
22716259 - Atrial fibrillation induction by transesophageal electrophysiology studies in patients ...
16809559 - Statin treatment is not associated with consistent alterations in inflammatory status o...
9509069 - Gonadal status is an important determinant of bone density in acromegaly.
23337159 - Bone mineral density in patients with nonalcoholic steatohepatitis among end-stage live...
9444579 - Efficacy of conservative treatment of lumbar disc herniation.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  International journal of clinical pharmacology research     Volume:  19     ISSN:  0251-1649     ISO Abbreviation:  Int J Clin Pharmacol Res     Publication Date:  1999  
Date Detail:
Created Date:  1999-09-23     Completed Date:  1999-09-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8110183     Medline TA:  Int J Clin Pharmacol Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  19-25     Citation Subset:  IM    
Affiliation:
Regional Center for Atherosclerosis Research, Pomeranian Academy of Medicine, Szczecin, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / pharmacology,  therapeutic use*
Arteriosclerosis / prevention & control
Clofibric Acid / analogs & derivatives*,  pharmacology,  therapeutic use
Diabetes Mellitus, Type 1 / drug therapy,  metabolism
Factor VII / drug effects*,  metabolism
Fibrinogen / drug effects*,  metabolism
Humans
Hyperlipidemias / drug therapy,  metabolism
Hypertension / drug therapy,  metabolism
Lipids / blood
Male
Middle Aged
Pilot Projects
Risk Factors
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Lipids; 31637-97-5/etofibrate; 882-09-7/Clofibric Acid; 9001-25-6/Factor VII; 9001-32-5/Fibrinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin.
Next Document:  Function of the hypothalamic adrenal axis in patients with fibromyalgia syndrome undergoing mud-pack...